iLoF is a digital health company pioneering a breakthrough AI-platform to accelerate the future of personalized drug discovery and development. Through advanced AI and Photonics, iLoF is collecting massive amounts of data to build a digital library of biomarkers and biological profiles, bringing together world-class physicists, biologists, and data scientists to get life-saving personalized treatments to patients faster. Recognized by CB Insights as one of the top Digital Health companies in the world and by the Financial Times as a Transformational Business in Healthcare, iLoF is supported by leading institutions like Microsoft Ventures, Mayfield or the Oxford University, and has been regularly featured by outlets like Tech Crunch, Wired, or Sifted as a rising star in AI-Driven Drug Discovery, Health Screening & Data Analytics.
Hzymes Biotechnology
Hzymes Biotechnology Co., Ltd. (Hzymes) is a high-tech enterprise specializing in the research and development, production, application and technical services of enzymes. we can provide customized services for raw materials, raw material intermediates, OEM reagents. Through the optimization of key components such as enhancers, stabilizers, and preservatives, the performance of the product has been greatly improved. As a product and service supplier, we are in partnership with over 100 Chinese and international lVD reagent manufacturers, and selling the products to 25 different countries. By constantly extending our product lines, Hzymes is committed to growing into a world-class enzyme products and services supplier.
Hong Kong Pavilion
Hong Kong possesses a distinct advantage in biotechnology development, recognized as one of the world’s leading fundraising hubs for biotech companies. With robust research and development capabilities, HK is home to five universities ranked among the top 100 globally, while InnoHK serves as a pivotal hub for R&D in life and health technologies. 16 companies from Hong Kong Science and Technoloy Parks Corporation (HKSTP) participate BIO25 in HK Pavilion. | Hong Kong Science & Technology Parks Corporation (HKSTP) is a leading innovation and technology hub established in 2002. It fosters a vibrant ecosystem for startups, enterprises, and researchers, offering incubation, acceleration, and investment opportunities. HKSTP operates Science Park, InnoCentre, and InnoParks across Hong Kong, driving advancements in life sciences, AI, fintech, and more. With strong global partnerships, state-of-the-art facilities, and talent development programs, HKSTP accelerates innovation and commercialization, contributing to Hong Kong’s position as a regional I&T leader.
HiComp
Established in 2014, HiComp Microtech stands as a premier original design manufacturer specializing in advanced microfluidics products and laboratory consumables. Our solutions boost precision, efficiency, and reliability from prototyping to mass production. Quality, performance and affordability are our priorities. | Established in 2014, HiComp Microtech is a leading original design manufacturer (ODM) specializing in advanced microfluidic products and laboratory consumables. Our ISO-certified and FDA-registered facilities span 100,000 sq. ft., including approximately 40,000 sq. ft. of high-standard cleanroom space. We provide precision, efficiency, and reliability from prototyping through volume production, serving renowned pharmaceutical and clinical diagnostic companies globally. With a proven track record, HiComp has successfully completed over 100 commercialized projects. Our services include: • Product Design • 3D Printing • CNC Micro Milling • MEMS Manufacturing • PDMS Manufacturing • Organoids/Organ on a Chip • Cleanroom Injection Molding • Surface Functionalization • Bonding & Sealing • Custom Microwell Plates • Assembly & Automation • Reagent Storage and Lyophilization
Health Holland Pavilion
The Health~hOlland Pavillion is the Dutch biotech industry association that connects, supports and represents entities active in healthcare, agrifood and the biobased economy. We are convinced that biotech makes life better and therefore our aim is to maximize the contribution of biotech innovations to our society’s health, sustainability and prosperity. | Top Sector Life Sciences & Health (Health~Holland) is a non-profit, working on behalf of the Netherlands, to drive innovation within the Life Sciences & Health (LSH) sector in the Netherlands. We leverage the power of (international) public-private collaboration to accelerate innovations and address societal challenges, helping to transform health and care. With our financing and connecting role, we strive to achieve both economic and societal impact. Interested in working with Dutch companies, exploring a location in the Netherlands, or simply looking for more information about the Dutch Life Sciences & Health ecosystem? Come connect with us at the Orange Pavilion! | Ready to explore opportunities in the Netherlands? The Netherlands, as Europe’s connected life sciences & health metropolis, has a lot to offer to the world and possesses a favorable innovation ecosystem and business climate for foreign companies. Here’s why: – A high concentration of life sciences & health businesses in a well-connected metropolis. – A strategic geographical location at the heart of Europe with advanced logistics. – Public-private partnerships offering opportunities for improved outcomes. – A highly collaborative ecosystem with world-class research and development. – A stable European economy with access to multicultural talent and the EMA (European Medicines Agency). Interested in collaborating with the Netherlands? We initiate, foster, and leverage international collaboration, acknowledging its crucial role in driving innovation, facilitating knowledge exchange, and promoting trade and investment. To support this, we offer a broad array of tools and initiatives designed to stimulate and sustain cross-border partnerships, including: – Sharing our knowledge and connecting our network; – Organizing visits to and from the Netherlands; – Representing the Dutch LSH sector alongside Dutch companies at international conferences; – Offering Start-up and SME support programs; – Financing public-private partnerships, a.o. Health~Holland International Kickstarter Call.
FINGERPAINT BRANDING
Fingerpaint Branding, formerly Leaderboard Branding, is a global naming and branding firm that delivers strategic insights and world-class creativity to every client, on every engagement. Built on the tenets of putting people first and taking pride in your work, Fingerpaint Branding has developed strong and strategic partnerships with healthcare, biopharma, consumer, and B2B companies. In the biopharma and healthcare space, Fingerpaint Branding supports clients in the early phases of clinical development. The expert strategists at Fingerpaint Branding have a unique ability to optimize a brand’s commercial potential while mitigating safety concerns and aligning to regulatory guidelines. With expertise in nonproprietary naming, clinical trial branding, global trade name development, and visual design, Fingerpaint Branding provides creative solutions through each phase of the drug development process. Fingerpaint Branding’s drug safety consulting and assessment capabilities help clients make crucial commercial decisions and regulatory submissions with confidence. Connect with us at fingerpaintbranding.com and follow us on LinkedIn. | Fingerpaint Branding is a global naming and branding consultancy delivering one-of-a-kind creativity to every partner. Our commitment to strong, strategic partnerships builds distinctive, memorable brands.
Eurogentec
Eurogentec is an international company founded in 1985 and part of Kaneka Corp. since 2010. Headquartered in Liege (Belgium) it provides products and services to scientists involved in the life science research, molecular diagnostics and therapeutic developments. Eurogentec has production sites in Europe and United States of America. The company is recognized as one of the major suppliers in the field of genomics and proteomics as well as a trusted US FDA inspected Contract Development and Manufacturing Organization (CDMO) for the bio-production of pharmaceuticals (vaccines and medicines). | Founded in 1985 and part of Kaneka Corporation since 2010, Eurogentec is a leading biotechnology and CDMO company specializing in GMP-certified manufacturing of starting materials and APIs. With facilities in Europe and the USA, we support plasmid DNA, mRNA, recombinant proteins, peptides, antibody fragments, and therapeutic oligonucleotides from early research to clinical and commercial production. Our expertise in process development and scale-up ensures high-quality solutions at every stage. Detailed Description of Products (Event Specific) max 500 characters in English – Plasmid DNA : Starting material & APIs including Nano-plasmids & Minicircle DNA. FastTrack: 4-month production. – mRNA : IVT mRNA (0.1g–50g), saRNA, gRNA with co-/post-transcriptional modifications. – Proteins : GMP production in E. coli & P. pastoris for biotech & pharma. – Conjugates : Chemically modified recombinant proteins for clinical use. – Therapeutic Oligos : ASOs, siRNA, aptamers, CpG oligos. – Peptides : Linear, cyclic & complex-modified. – Antibody Fragments : scFv, Fab, VHH, bispecifics. | Eurogentec—part of Kaneka Corp. since 2010—is a leading international company founded in 1985 and headquartered in Belgium. Accredited by the Belgian AFMPS, US FDA, and Japanese MHLW, we deliver trusted solutions to the life sciences, molecular diagnostics, and therapeutic development sectors. As a major supplier in genomics (oligonucleotides, qPCR kits, reagents) and proteomics (custom and catalog antibodies, peptides), we also act as a reliable CDMO for process development and GMP manufacturing of vaccines and medicines—including therapeutic oligonucleotides, peptides, plasmids, recombinant proteins, mRNA and VHH antibodies. Our comprehensive services cover process transfer, development and optimization, scale-up, tox and clinical batches, GMP and GMP-like manufacturing, Quality Control, QA release, and ICH stability studies. From early-phase development to commercialization, Eurogentec is your single partner for every step of the journey.
CNCure Co., Ltd.
CNCure is a pioneering biotech startup dedicated to revolutionizing cancer therapy and diagnostics. We specialize in developing bacteria-based cancer immunotherapeutics and theranostic platforms leveraging microbial theapeutics and nuclear medicine. One of our core technologies is the Salmonella-based Armed Microbe (SAM) platform, which utilizes innovative approaches to target tumors and enhance anticancer immune responses. Our flagship products, CNC-101 and CNC-105, directly target tumors, induce immune responses, and establish long-term antitumor immunological memory to prevent recurrence. In addition, CNCure is advancing diagnostic technologies with radiotracer-based tools for the high-sensitivity detection of fatal diseases such as fungal infections. Our [18F]FDS and [18F]DMPY2 tracers enable high-resolution visualization of gram-negative bacterial and fungal infections and malignant melanoma, respectively. CNCure is dedicated to pioneering innovations in cancer treatment, striving to improve patient outcomes and quality of life on a global scale. By actively participating in numerous national and international R&D projects, we continue to drive groundbreaking research and development. Our extensive patent portfolio is a testament to our technological excellence and commitment to shaping the future of oncology. Founded in 2019 by leading experts in cancer immunotherapy and radiopharmaceuticals, CNCure has developed a robust scientific foundation, a cutting-edge technology platform, and a strong pipeline. In the second half of 2024, we were honored to be one of only 14 companies, out of over 100 applicants, selected for Johnson & Johnson’s JLABS Korea program, which aims to accelerate life-science innovation. As we advance the clinical development and commercialization of our theranostic candidates, we actively seek joint-development partnerships and investments to expand our global presence. Our vision is to revolutionize cancer treatment through groundbreaking bacteria-based immunotherapies and radiopharmaceuticals that address critical unmet medical needs. | CNCure Co., Ltd. is a pioneering biotechnology company based in Hwasun, Republic of Korea, dedicated to revolutionizing cancer therapy and diagnostics. Founded in 2019, CNCure specializes in bacteria‑based cancer immunotherapeutics and integrated theranostic platforms leveraging microbial and nuclear medicine. The company’s lead candidate, CNC‑101, is a next‑generation bacterial immunotherapy built on attenuated Salmonella typhimurium technology, designed to selectively colonize the tumor microenvironment and reprogram it into an immuno‑active state that enhances anti‑tumor immune responses. Preclinical data demonstrate promising efficacy and safety profiles across multiple solid tumor models. Beyond immuno‑oncology, CNCure is advancing radiopharmaceutical and theranostic platforms that combine imaging and therapy for improved tumor targeting, treatment monitoring, and personalized decision‑making. CNCure actively pursues global partnerships and business development to translate its innovative platforms into clinical applications that address unmet medical needs. CNCure continues to present its scientific and clinical progress at major international conferences.